<DOC>
	<DOCNO>NCT00254579</DOCNO>
	<brief_summary>CP-675,206 fully human monoclonal antibody ( mAb ) . It bind CTLA4 molecule , express surface activate T lymphocytes . CP-675,206 thought stimulate patient ' immune system attack tumor . CP-675,206 expect direct effect tumor cell . CP-675,206 show induce durable tumor response patient metastatic melanoma Phase 1 Phase 2 clinical study .</brief_summary>
	<brief_title>Study CP-675,206 Refractory Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Surgically incurable Stage III IV melanoma One prior systemic treatment metastatic melanoma Measurable disease Eastern Cooperative Oncology Group ( ECOG ) PS = 0 1 Melanoma ocular origin Received prior vaccine Received prior CTLA4inhibiting agent History , significant risk , chronic inflammatory autoimmune disease Potential requirement systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>refractory melanoma</keyword>
	<keyword>malignant melanoma</keyword>
</DOC>